|
Variable
|
Good downstaging
|
Poor downstaging
|
P
|
Odds Ratio (95%CI)
|
|---|
|
Training cohort
|
|
Pretreatment T stage
| | |
0.04
|
10.14 (1.11–92.55)
|
|
T2–3
|
19 (95%)
|
33 (65%)
| | |
|
T4
|
1 (5%)
|
18 (35)
| | |
|
Tumor differentiation
| | |
0.032
|
4.21 (1.13–15.68)
|
|
Well/Moderately
|
14 (70%)
|
20 (40%)
| | |
|
Poorly/Undifferentiated
|
6 (30%)
|
31 (60%)
| | |
|
CEA clearance pattern
| | |
0.002
|
8.25 (2.19–31.10)
|
|
Exponential decrease (R2≧0.9) |
15 (75%)
|
16 (31%)
| | |
|
Non-exponential decrease (R2 < 0.9)
|
5 (25%)
|
35 (69%)
| | |
|
Validation cohort
|
|
Pretreatment T stage
| | |
0.108
|
0.31 (0.08–1.29)
|
|
T2–3
|
26 (78%)
|
42 (86%)
| | |
|
T4
|
0
|
7 (14%)
| | |
|
Tumor differentiation
| | |
0.752
|
1.22 (0.36–4.09)
|
|
Well/Moderately
|
19 (73%)
|
37 (76%)
| | |
|
Poorly/Undifferentiated
|
7 (27%)
|
12 (24%)
| | |
|
CEA clearance pattern
| | |
0.008
|
4.28 (1.47–12.43)
|
|
Exponential decrease (R2≧0.9) |
18 (69%)
|
18 (37%)
| | |
|
Non-exponential decrease (R2 < 0.9)
|
8 (31%)
|
31 (63%)
| | |
- The p value in boldface means statistically significant, that is, less than 0.05
